Wildebeast
The true worth of VCR will be seen one day.When - who knows. What has happened to it, is IMO, an injustice to the company and its shareholders. Some of it may be self inflicted, that's history now.Moving forward, they need a bit more money, a relatively small percentage of what has been spent to date, to get them to a stage when they can be self funding. There will still be ongoing R and D costs, so there should be.When they receive FDA approval for BTT there will be a quick change to profitability. Once they, and they will, receive DT approval they will become massively profitable.Look at the figures, 82% of recipients alive and with a better quality of life after a year, and the promise of better to come.50000 odd people a year as candidates for a new heart. One other company Thoratec+ Heartware, as serious competitors.
Shareholders who funded the vast majority of this work over the past 6 or 8 years have every reason to want to hold their positions. They should be allowed to do so and IMO the management will have this firmly on the agenda when a deal is done.
What the company is worth now is hard to quantify, but Heartware were worth $420 odd million to Thoratec with a good product but a long way behind VCR and with unknown challenges ahead.
The real worth of the company will be seen in the future and as a long term SH I hope I am given the opportunity to share in the success of the product
VCR
ventracor limited
